Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Lechner, SG; Mayer, M; Boehm, S.
Activation of M1 muscarinic receptors triggers transmitter release from rat sympathetic neurons through an inhibition of M-type K+ channels.
J Physiol. 2003; 553(Pt 3):789-802 Doi: 10.1113/jphysiol.2003.052449 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Böhm Stefan
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Acetylcholine has long been known to excite sympathetic neurons via M1 muscarinic receptors through an inhibition of M-currents. Nevertheless, it remained controversial whether activation of muscarinic receptors is also sufficient to trigger noradrenaline release from sympathetic neurons. In primary cultures of rat superior cervical ganglia, the muscarinic agonist oxotremorine M inhibited M-currents with half-maximal effects at 1 microM and induced the release of previously incorporated [3H]noradrenaline with half-maximal effects at 10 microM. This latter action was not affected by the nicotinic antagonist mecamylamine which, however, abolished currents through nicotinic receptors elicited by high oxotremorine M concentrations. Ablation of the signalling cascades linked to inhibitory G proteins by pertussis toxin potentiated the release stimulating effect of oxotremorine M, and the half-maximal concentration required to stimulate noradrenaline release was decreased to 3 microM. Pirenzepine antagonized the inhibition of M-currents and the induction of release by oxotremorine M with identical apparent affinity, and both effects were abolished by the muscarinic toxin 7. These results indicate that one muscarinic receptor subtype, namely M1, mediates these two effects. Retigabine, which enhances M-currents, abolished the release induced by oxotremorine M, but left electrically induced release unaltered. Moreover, retigabine shifted the voltage-dependent activation of M-currents by about 20 mV to more negative potentials and caused 20 mV hyperpolarisations of the membrane potential. In the absence of retigabine, oxotremorine M depolarised the neurons and elicited action potential discharges in 8 of 23 neurons; in its presence, oxotremorine M still caused equal depolarisations, but always failed to trigger action potentials. Action potential waveforms caused by current injection were not affected by retigabine. These results indicate that the inhibition of M-currents is the basis for the stimulation of transmitter release from sympathetic neurons via M1 muscarinic receptors.
Find related publications in this database (using NLM MeSH Indexing)
Animals -
Animals, Newborn -
Carbamates - pharmacology
Cells, Cultured -
Evoked Potentials - drug effects
Mecamylamine - pharmacology
Membrane Potentials - drug effects
Muscarinic Agonists - pharmacology
Neurons - cytology Neurons - drug effects Neurons - physiology
Norepinephrine - secretion
Oxotremorine - analogs & derivatives Oxotremorine - pharmacology
Pertussis Toxin - pharmacology
Phenylenediamines - pharmacology
Potassium Channels, Voltage-Gated - antagonists & inhibitors
Rats -
Rats, Sprague-Dawley -
Receptor, Muscarinic M1 - drug effects Receptor, Muscarinic M1 - physiology
Superior Cervical Ganglion - cytology Superior Cervical Ganglion - physiology
Tetrodotoxin - pharmacology

© Med Uni Graz Impressum